Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17419151 | Compositions and Methods for Promoting Angiogenesis in the Eye | Non-Final OA | The Regents of the University of California |
| 17784907 | STABLE MONOMERIC INSULIN FORMULATIONS ENABLED BY SUPRAMOLECULAR PEGYLATION OF INSULIN ANALOGUES | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17919008 | ANTIVIRAL STRUCTURALLY-STABILIZED ACE2 HELIX 1 PEPTIDES AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17473362 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES USING FNDC5 | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17441188 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | Non-Final OA | The Johns Hopkins University |
| 17783704 | USE OF THE GDF-5 MUTANT FOR THE TREATMENT OF PAIN AND CARTILAGE DESTRUCTION | Final Rejection | Merck Patent GmbH |
| 16093758 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18750233 | ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17013245 | NOVEL ANTICANCER FUSION PROTEIN AND USE THEREOF | Non-Final OA | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17600922 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING | Final Rejection | Versitech Limited |
| 17100889 | CELL PENETRATING MOLECULE | Non-Final OA | United Kingdom Research and Innovation |
| 18017982 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | Non-Final OA | City of Hope |
| 17439641 | NEW INHIBITORS OF LRRK2/PP1 INTERACTION | Non-Final OA | Institut National de la Sante et de la Recherche Medicale |
| 18421886 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | Non-Final OA | ImmunoForge Co., LTD. |
| 18269134 | COMBINATION THERAPY OF INSULINOTROPIC PEPTIDE AND GLP-2, FOR PREVENTING OR TREATING SHORT BOWEL SYNDROME | Non-Final OA | HANMI PHARM. CO., LTD. |
| 16106348 | Composition and Nutritional Supplement Made Therefrom | Final Rejection | Lonza Greenwood LLC |
| 17906811 | PEPTOID-CONTAINING PERSONAL LUBRICANT | Non-Final OA | MAXWELL BIOSCIENCES, INC. |
| 18270019 | PEPTIDE FOR USE IN THE TREATMENT OR PREVENTION OF COVID-19 | Non-Final OA | Instytut Biochemii I Biofizyki Polskiej Akademii Nauk |
| 17435267 | NEW VACCINAL STRATEGY TO PREVENT OR TREAT RHUMATOID ARTHRITIS | Non-Final OA | ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE |
| 17906763 | COMPOSITION AND KIT FOR REMOVING LIPOPOLYSACCHARIDE | Non-Final OA | HLB SCIENCE INC. |
| 17799201 | MELANOMA THERAPEUTICS | Non-Final OA | ESCAPE THERAPEUTICS, INC. |
| 17799252 | METHOD FOR PREVENTING, TREATING OR DELAYING HEART FAILURE BY USING NEUREGULIN, AND COMPOSITION | Non-Final OA | Zensun (Shanghai) Science & Technology, Co., Ltd. |
| 17877380 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | Non-Final OA | Alzheon, Inc. |
| 17794935 | GROWTH FACTOR FORMULATION FOR CONDITION ASSOCIATED WITH OTIC EVENT | Non-Final OA | DOMPÉ FARMACEUTICI S.P.A. |
| 17787228 | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR | Non-Final OA | Cella Therapeutics, LLC |
| 17629956 | Osteocrin, Lebetin or ANP for Destroying Bacterial Biofilms | Final Rejection | Université de Rouen-Normandie |
| 17394854 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR INHIBITING VIRAL INFECTION AND SPREAD | Final Rejection | Peter G. Carroll |
| 17235035 | THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE | Non-Final OA | Therapeutics By Design, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy